Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „obinutuzumab“
Suchtreffer
Begriffe & Kennungen
Calquence · 4.8 · 56 Of the 284 patients treated with Calquence in combination with venetoclax and obinutuzumab, discontinuation
Eintrag öffnenCalquence · 4.8 · Calquence + Calquence + Calquence + Calquence + BR venetoclax venetoclax + Obinutuzumab N=297 N=291 obinutuzum
Eintrag öffnenCalquence · 4.8 · Calquence + Calquence + Calquence + Calquence + BR venetoclax venetoclax + Obinutuzumab N=297 N=291 obinutuzum
Eintrag öffnenCalquence · 4.8 · Calquence in combination with obinutuzumab
Eintrag öffnenCalquence · 4.8 · Calquence in combination with obinutuzumab
Eintrag öffnenCalquence · 4.8 · Calquence in combination with venetoclax and obinutuzumab
Eintrag öffnenCalquence · 4.8 · Calquence in combination with venetoclax and obinutuzumab
Eintrag öffnenCalquence · 4.8 · Of the 223 patients in clinical studies of Calquence in combination of obinutuzumab therapy, 47% were greater
Eintrag öffnenCalquence · 4.8 · Of the 223 patients in clinical studies of Calquence in combination of obinutuzumab, 47% were greater than 65
Eintrag öffnenCalquence · 4.8 · Of the 223 patients treated with Calquence in combination with obinutuzumab, discontinuation of Calquence due
Eintrag öffnenCalquence · 4.8 · Of the 223 patients treated with Calquence in combination with obinutuzumab, discontinuation of Calquence due
Eintrag öffnenCalquence · 4.8 · Of the 223 patients treated with Calquence in combination with obinutuzumab, the most common (≥ 20%) ADRs of a
Eintrag öffnenCalquence · 4.8 · Of the 223 patients treated with Calquence in combination with obinutuzumab, the most common (≥ 20%) ADRs of a
Eintrag öffnenCalquence · 4.8 · Of the 284 patients treated with Calquence in combination with venetoclax and obinutuzumab, 24% were greater t
Eintrag öffnenCalquence · 4.8 · Of the 284 patients treated with Calquence in combination with venetoclax and obinutuzumab, 24% were greater t
Eintrag öffnenCalquence · 4.8 · Of the 284 patients treated with Calquence in combination with venetoclax and obinutuzumab, discontinuation of
Eintrag öffnenCalquence · 4.8 · Of the 284 patients treated with Calquence in combination with venetoclax and obinutuzumab, severe (Grade ≥ 3)
Eintrag öffnenCalquence · 4.8 · Of the 284 patients treated with Calquence in combination with venetoclax and obinutuzumab, severe (Grade ≥ 3)
Eintrag öffnenCalquence · 4.8 · Of the 284 patients treated with Calquence in combination with venetoclax and obinutuzumab, the most common (≥
Eintrag öffnenCalquence · 4.8 · Of the 284 patients treated with Calquence in combination with venetoclax and obinutuzumab, the most common (≥
Eintrag öffnen